LIU Ruidi
1.Academy of Chinese Medica Sciences, Henan University of Chinese Medicine, Zhengzhou 450046, ChinaXU Jiangyan
1.Academy of Chinese Medica Sciences, Henan University of Chinese Medicine, Zhengzhou 450046, ChinaXIE Zhishen
1.Academy of Chinese Medica Sciences, Henan University of Chinese Medicine, Zhengzhou 450046, ChinaZHANG Xiaowei
1.Academy of Chinese Medica Sciences, Henan University of Chinese Medicine, Zhengzhou 450046, ChinaCHEN Jie
2.International Academic Affairs Department, Management and Science University, Negeri Selangor 47300, MalaysiaZHANG Zhenqiang
1.Academy of Chinese Medica Sciences, Henan University of Chinese Medicine, Zhengzhou 450046, China1.Academy of Chinese Medica Sciences, Henan University of Chinese Medicine, Zhengzhou 450046, China.2.International Academic Affairs Department, Management and Science University, Negeri Selangor 47300, Malaysia
R-33
Signal transducer and activator of transcription 3 (STAT3) is known to modulate the expression of genes related to cell transformation, proliferation, and survival, making it a significant target for cancer therapy. Recent research has also highlighted the crucial involvement of aberrant STAT3 activation in the pathogenesis of diabetic kidney disease (DKD). Accordingly, this article focuses on the therapeutic potential of targeting STAT3 in DKD. The structure of STAT3, its mechanisms of activity regulation, mechanisms of abnormal STAT3 activation in DKD, and a summary of the current research is provided. The review aims provide a reference for research into the pathogenesis of DKD and the development of new drugs.
